Skip to main content Accessibility help
Hostname: page-component-7d8f8d645b-r82c8 Total loading time: 0 Render date: 2023-05-27T22:06:13.975Z Has data issue: false Feature Flags: { "useRatesEcommerce": true } hasContentIssue false

Section IX - Medication reversal and restarting in patients with iatrogenic strokes

Published online by Cambridge University Press:  20 October 2016

Alexander Tsiskaridze
Sarajishvili Institute of Neurology, Tblisi State University, Georgia
Arne Lindgren
Department of Neurology, University Hospital Lund, Sweden
Adnan I. Qureshi
Department of Neurology, University of Minnesota
Get access
Treatment-Related Stroke
Including Iatrogenic and In-Hospital Strokes
, pp. 255 - 264
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


van Asch, C J, Luitse, M J, Rinkel, G J, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: A systematic review and meta-analysis. Lancet Neurology. 2010; 9:167–76.
Flaherty, M L, Kissela, B, Woo, D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007; 68:116–21.
Huhtakangas, J, Tetri, S, Juvela, S, et al. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: A longitudinal population-based study. Stroke. 2011; 42:2431–5.
Hart, R G, Boop, B S, Anderson, D C. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995; 26:1471–7.
Jeffree, R L, Gordon, D H, Sivasubramaniam, R, Chapman, A. Warfarin related intracranial haemorrhage: A case-controlled study of anticoagulation monitoring prior to spontaneous subdural or intracerebral haemorrhage. Journal of Clinical Neuroscience. 2009; 16:882–5.
Dequatre-Ponchelle, N, Henon, H, Pasquini, M, et al. Vitamin K antagonists-associated cerebral hemorrhages: What are their characteristics? Stroke. 2013; 44:350–5.
Keeling, D, Baglin, T, Tait, C, et al. Guidelines on oral anticoagulation with warfarin – fourth edition. British Journal of Haematology. 2011; 154:311–24.
Limdi, N A, Veenstra, D L. Warfarin pharmacogenetics. Pharmacotherapy. 2008; 28:1084–97.
Watanabe, M, Siddiqui, F M, Qureshi, A I. Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. Neurocritical Care. 2012; 16:203–9.
Di Nisio, M, Middeldorp, S, Buller, H R. Direct thrombin inhibitors. New England Journal of Medicine. 2005; 353:1028–40.
van Ryn, J, Stangier, J, Haertter, S, et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis and Haemostasis. 2010; 103:1116–27.
Yeh, C H, Fredenburgh, J C, Weitz, J I. Oral direct factor Xa inhibitors. Circulation Research. 2012; 111:1069–78.
Kamal, A H, Tefferi, A, Pruthi, R K. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clinic Proceedings. 2007; 82:864–73.
Miyares, M A, Davis, K. Newer oral anticoagulants: A review of laboratory monitoring options and reversal agents in the hemorrhagic patient. American Journal of Health-System Pharmacy. 2012; 69:1473–84.
Samama, M M, Martinoli, J L, LeFlem, L, et al. Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor. Thrombosis and Haemostasis. 2010; 103:815–25.
Samama, M M, Guinet, C. Laboratory assessment of new anticoagulants. Clinical Chemistry and Laboratory Medicine. 2011; 49:761–72.
Stangier, J, Rathgen, K, Stahle, H, Gansser, D, Roth, W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. British Journal of Clinical Pharmacology. 2007; 64:292303.
Lippi, G, Favaloro, E J. Activated partial thromboplastin time: New tricks for an old dogma. Seminars in Thrombosis and Hemostasis. 2008; 34:604–11.
Wong, P C, Crain, E J, Xin, B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: In vitro, antithrombotic and antihemostatic studies. Journal of Thrombosis and Haemostasis. 2008; 6:820–9.
Bara, L, Mardiguian, J, Samama, M. In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities. Thrombosis Research. 1990; 57:585–92.
Harder, S, Parisius, J, Picard-Willems, B. Monitoring direct FXa-inhibitors and fondaparinux by prothrombinase-induced clotting time (PiCT): Relation to FXa-activity and influence of assay modifications. Thrombosis Research. 2008; 123:396403.
Qureshi, A I, Tuhrim, S, Broderick, J P, et al. Spontaneous intracerebral hemorrhage. New England Journal of Medicine. 2001; 344:1450–60.
Goldstein, J N, Gilson, A J. Critical care management of acute intracerebral hemorrhage. Current Treatment Options in Neurology. 2011; 13:204–16.
Masotti, L, Di Napoli, M, Godoy, D A, et al. The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy. International Journal of Stroke. 2011; 6:228–40.
Qureshi, A I. Intracerebral hemorrhage specific intensity of care quality metrics. Neurocritical Care. 2011; 14:291317.
Goodnough, L T, Shander, A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood. 2011; 117:6091–9.
Riegert-Johnson, D L, Volcheck, G W. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): A 5-year retrospective review. Annals of Allergy, Asthma & Immunology. 2002; 89:400–6.
Aguilar, M I, Hart, R G, Kase, C S, et al. Treatment of warfarin-associated intracerebral hemorrhage: Literature review and expert opinion. Mayo Clinic Proceedings. 2007; 82:8292.
Benjamin, R J, McLaughlin, L S. Plasma components: Properties, differences, and uses. Transfusion. 2012; 52(Suppl 1):9S19S.
Goldstein, J N, Thomas, S H, Frontiero, V, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke. 2006; 37:151–5.
Goodnough, L T. A reappraisal of plasma, prothrombin complex concentrates, and recombinant factor VIIa in patient blood management. Critical Care Clinics. 2012; 28:413–26.
Silliman, C C, McLaughlin, N J. Transfusion-related acute lung injury. Blood Reviews. 2006; 20:139–59.
Pandey, S, Vyas, G N. Adverse effects of plasma transfusion. Transfusion. 2012; 52(Suppl 1):65S79S.
Fredriksson, K, Norrving, B, Stromblad, L G. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke. 1992; 23:972–7.
Huttner, H B, Schellinger, P D, Hartmann, M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: Comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006; 37:1465–70.
Switzer, J A, Rocker, J, Mohorn, P, et al. Clinical experience with three-factor prothrombin complex concentrate to reverse warfarin anticoagulation in intracranial hemorrhage. Stroke. 2012; 43:2500–2.
Wiedermann, C J, Stockner, I. Warfarin-induced bleeding complications: clinical presentation and therapeutic options. Thrombosis Research. 2008; 122(Suppl 2):S1318.
Dager, W E, King, J H, Regalia, R C, et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy. 2006; 26:1091–8.
Mayer, S A, Brun, N C, Begtrup, K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. New England Journal of Medicine. 2005; 352:777–85.
Mayer, S A, Brun, N C, Begtrup, K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. New England Journal of Medicine. 2008; 358:2127–37.
Narayan, R K, Maas, A I, Marshall, L F, et al. Recombinant factor VIIa in traumatic intracerebral hemorrhage: Results of a dose-escalation clinical trial. Neurosurgery. 2008; 62:776–86.
Yuan, Z H, Jiang, J K, Huang, W D, et al. A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia. Journal of Clinical Neuroscience. 2010; 17:685–93.
Morgenstern, L B, Hemphill, J C 3rd, Anderson, C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010; 41:2108–29.
Pernod, G, Godier, A, Gozalo, C, et al. French National Authority for H. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thrombosis Research. 2010; 126:e167–74.
Shander, A G L, Ratko, T, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (novoseven) therapy. Pharmacol Ther. 2005; 644.
Vincent, J L, Rossaint, R, Riou, B, et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding: A European perspective. Critical Care. 2006; 10:R120.
Rosovsky, R P, Crowther, M A. What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008. Hematology. 2008;36–8.
Fernandes, H M, Siddique, S, Banister, K, et al. Continuous monitoring of ICP and CPP following ICH and its relationship to clinical, radiological and surgical parameters. Acta Neurochirurgica. Supplement. 2000; 76:463–6.
Brott, T, Adams, H P Jr., Olinger, C P, et al. Measurements of acute cerebral infarction: A clinical examination scale. Stroke. 1989; 20:864–70.
Teasdale, G, Jennett, B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974; 2:81–4.
Diringer, M N, Edwards, D F. Admission to a neurologic/neurosurgical intensive care unit is associated with reduced mortality rate after intracerebral hemorrhage. Critical Care Medicine. 2001; 29:635–40.
Flaherty, M L, Tao, H, Haverbusch, M, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008; 71:1084–9.
Steiner, T, Rosand, J, Diringer, M. Intracerebral hemorrhage associated with oral anticoagulant therapy: Current practices and unresolved questions. Stroke. 2006; 37:256–62.
Webb, H D, Griffin, C A. Cytogenetic study of acoustic neuroma. Cancer Genetics and Cytogenetics. 1991; 56:83–4.
Schulman, S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. New England Journal of Medicine. 2003; 349:675–83.
Qureshi, A I, Majidi, S, Chaudhry, S A, Qureshi, M H, Suri, M F. Validation of intracerebral hemorrhage-specific intensity of care quality metrics. Journal of Stroke and Cerebrovascular Diseases. 2013; 22:661–7.
Fernlof, G, Sjostrom, B M, Lindell, K M, Wall, U E. Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin. Blood coagulation & Fibrinolysis. 2009; 20:667–74.
Monroe, D M, Hoffman, M, Oliver, J A, Roberts, H R. Platelet activity of high-dose factor VIIa is independent of tissue factor. British Journal of Haematology. 1997; 99:542–7.
Leissinger, C A, Blatt, P M, Hoots, W K, Ewenstein, B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature. American Journal of Hematology. 2008; 83:137–43.
Stangier, J, Rathgen, K, Stahle, H, Mazur, D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study. Clinical Pharmacokinetics. 2010; 49:259–68.
Crawley, F, Bevan, D, Wren, D. Management of intracranial bleeding associated with anticoagulation: Balancing the risk of further bleeding against thromboembolism from prosthetic heart valves. Journal of Neurology, Neurosurgery, and Psychiatry. 2000; 69:396–8.
Punthakee, X, Doobay, J, Anand, S S. Oral-anticoagulant-related intracerebral hemorrhage. Thrombosis Research. 2002; 108:31–6.
Phan, T G, Koh, M, Wijdicks, E F. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Archives of Neurology. 2000; 57:1710–13.
Wijdicks, E F, Schievink, W I, Brown, R D, Mullany, C J. The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. Neurosurgery. 1998; 42:769–73.
Leker, R R, Abramsky, O. Early anticoagulation in patients with prosthetic heart valves and intracerebral hematoma. Neurology. 1998; 50:1489–91.
Bertram, M, Bonsanto, M, Hacke, W, Schwab, S. Managing the therapeutic dilemma: Patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation. Journal of Neurology. 2000; 247:209–14.
Butler, A C, Tait, R C. Restarting anticoagulation in prosthetic heart valve patients after intracranial haemorrhage: A 2-year follow-up. British Journal of Haematology. 1998; 103:1064–6.
Kawamata, T, Takeshita, M, Kubo, O, et al. Management of intracranial hemorrhage associated with anticoagulant therapy. Surgical Neurology. 1995; 44:438–42.
Babikian, V L, Kase, C S, Pessin, M S, Caplan, L R, Gorelick, P B. Resumption of anticoagulation after intracranial bleeding in patients with prosthetic heart valves. Stroke. 1988; 19:407–8.
Gomez, C R, Sandhu, J, Mehta, P. Resumption of anticoagulation during hypertensive cerebral hemorrhage with prosthetic heart valve. Stroke. 1988; 19:407.

Save book to Kindle

To save this book to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the or variations. ‘’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats